Nanobodies Raised Against Monomeric Ɑ-Synuclein Inhibit Fibril Formation and Destabilize Toxic Oligomeric Species

Marija Iljina,Liu Hong,Mathew H. Horrocks,Marthe H. Ludtmann,Minee L. Choi,Craig D. Hughes,Francesco S. Ruggeri,Tim Guilliams,Alexander K. Buell,Ji-Eun Lee,Sonia Gandhi,Steven F. Lee,Clare E. Bryant,Michele Vendruscolo,Tuomas P. J. Knowles,Christopher M. Dobson,Erwin De Genst,David Klenerman

DOI: https://doi.org/10.1186/s12915-017-0390-6

IF: 7.364

2017-01-01

BMC Biology

Abstract:BACKGROUND:The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common neurodegenerative disorders including Parkinson's disease. One widely explored therapeutic strategy for these conditions is the use of antibodies to target aggregated ɑS, although a detailed molecular-level mechanism of the action of such species remains elusive. Here, we characterize ɑS aggregation in vitro in the presence of two ɑS-specific single-domain antibodies (nanobodies), NbSyn2 and NbSyn87, which bind to the highly accessible C-terminal region of ɑS.RESULTS:We show that both nanobodies inhibit the formation of ɑS fibrils. Furthermore, using single-molecule fluorescence techniques, we demonstrate that nanobody binding promotes a rapid conformational conversion from more stable oligomers to less stable oligomers of ɑS, leading to a dramatic reduction in oligomer-induced cellular toxicity.CONCLUSIONS:The results indicate a novel mechanism by which diseases associated with protein aggregation can be inhibited, and suggest that NbSyn2 and NbSyn87 could have significant therapeutic potential.